INTRODUCTION {#ss1}
============

The primary function of the uterus is supporting fertility, and the endometrium is the layer critically involved in receiving an embryo, facilitating implantation and decidualization, and supporting embryo growth and development until placentation ([@ref24]). The uterus is a target tissue of ovarian steroid hormones. Estradiol (E2) stimulates endometrial proliferation and growth, while progesterone (P4) suppresses E2 induced epithelial cell proliferation, concomitant with initiation of stromal cell differentiation ([@ref24]). These dynamic changes are necessary for embryo implantation and successful pregnancy ([@ref29]). The endometrium undergoes well-defined and regulated gene expression in preparation for implantation ([@ref7]).

The physiological effects of P4 are mediated by the progesterone receptor (PGR). P4 and PGR together play a central role in reproductive events associated with the establishment and maintenance of pregnancy. PGR regulates implantation, decidualization, and glandular development via a complex paracrine signaling network ([@ref33]; [@ref1]; [@ref2]). The pivotal role of PGR within reproductive tissues causes it to be an area of focus within reproductive diseases ([@ref31]). Specifically, reduced expression of PGR has been associated with endometriosis, a prevalent disease in women's health ([@ref9]). Overall, aberrations of steroid hormone signaling can be found in many uterine disorders including infertility, endometriosis, endometrial cancer, and uterine leiomyoma ([@ref13]; [@ref16]; [@ref25]; [@ref36]).

AT-rich interaction domain 1a (ARID1A) is one subunsit within the SWItch/Sucrose Non-Fermentable (SWI/SNF) chromatin remodeling complex ([@ref3]). It is located in chromosomal region 1p36, which is a region that is often deleted within many different forms of cancer ([@ref3]; [@ref30]). A high frequency of mutation of ARID1A in cancers, specifically endometrioid cancer of the uterus and ovarian clear cell and endometrioid cancer, has revealed the potential of ARID1A to be defined as a tumor suppressor ([@ref17]; [@ref10]). ARID1A is able to inhibit tumor growth and cellular proliferation ([@ref11]). Several studies have linked SWI/SNF and ARID1A to transcriptional regulation, particularly nuclear hormone-induced transcription and expression of cell cycle regulators ([@ref23]; [@ref27]; [@ref34]). Previously, we have shown that ARID1A protein levels are lower during both the proliferative and secretory phases, in epithelial and stromal cells of women with endometriosis compared to those without ([@ref19]). Ablation of *Arid1a* in the murine uterus results in the inability to inhibit E2-induced epithelial cell proliferation and E2-responsive target gene expression ([@ref19]). However, the molecular mechanism of ARID1A action in steroid hormone regulation and pregnancy is not well studied.

Proline-rich acidic protein 1 (PRAP1) is a secretory protein of 149 amino acids, with a 20 amino acid signal peptide at its N-terminal. PRAP1 has been identified as a differentially expressed gene in the pregnant uterus of rodents ([@ref18]). It is strongly expressed in the late pregnant uterus but disappears from the uterus within 3 days after birth ([@ref18]). Human *PRAP1* mRNA is detected in the gastrointestinal tract, liver, and kidney. PRAP1 is localized in the epithelial lining of the colon and cervix, the hepatocytes, and the kidney proximal and distal tubules ([@ref37]). PRAP1 plays an important role in maintaining normal growth homeostasis in epithelia (Lanemo [@ref20]; [@ref37]). PRAP1 is a p53-responsive gene induced by genotoxic stress ([@ref14]). It is an interacting partner of MAD1 and has a suppressive role in mitotic checkpoint signaling in hepatocellular carcinoma ([@ref28]). *Prap1* mRNA is highly expressed in the uterine luminal epithelium of gestation day (GD) 0.5 in mice, disappears in the preimplantation day 3.5 uterus, and reappears abundantly in the luminal epithelium after embryo implantation ([@ref6]). Therefore, PRAP1 is suggested as a marker for successful embryo implantation ([@ref6]).

While *Prap1* is up-regulated by E2, it is down-regulated by P4 ([@ref6]; [@ref35]). However, the regulation of PRAP1 in the uterus is still elusive. In order to explore the regulation of PRAP1 expression in the uterus, we investigated the expression of PRAP1 in the uterus of *Pgr* knockout (PRKO) and uterine specific *Arid1a* knockout (*Pgr^cre/+^Arid1a^f/f^*; *Arid1a^d/d^*) mice. We also evaluated the regulation of PRAP1 in response to steroid hormones in the uterus.

MATERIALS AND METHODS {#ss2}
=====================

1.. Animals and tissue collection {#ss3}
---------------------------------

All mouse experiments were approved by the Institutional Animal Care and Use Committee of Michigan State University (IACUC number: 11/16-192-00). For the uteri samples during early pregnancy, wild C57BL/6 female mice at 8 weeks of age were individually mated with wild-type male mice and uteri were collected at different time points of pregnancy. The initiation of pregnancy was marked by the presence of the postcoital vaginal plug as day 0.5 of gestation (GD 0.5) for early pregnancy study. In order to investigate the expression of PRAP1 by PGR and ARID1A in the uterus, we used PRKO and *Arid1a^d/d^* mice ([@ref22]; [@ref19]). We previously generated mice with conditional ablation of *Arid1a* in the PGR positive cells (*Arid1a^d/d^*) to study the role of *Arid1a* in the uterus ([@ref19]). Uterine tissues were collected from both horns then were stored at −80°C for RNA or fixed in 4% paraformaldehyde (vol/vol) and paraffin embedded.

To study PRAP1 expression by steroid hormone regulation, wild-type C57BL/6 mice, *Arid1a^d/d^* or PRKO mice at 6 weeks of age underwent bilateral ovariectomy. After at least 2 weeks to eliminate endogenous ovarian hormone completely, the mice were given subcutaneous injection with vehicle (sesame oil) or P4 (1mg/mouse) (n=3 per genotype per treatment). The uteri were collected at 6 hours after the steroid hormone injection.

To study PRAP1 expression by steroid hormone regulation, wild-type C57BL/6 mice, *Arid1a^d/d^* or PRKO mice at 6 weeks of age underwent bilateral ovariectomy. After at least 2 weeks to eliminate endogenous ovarian hormone completely, the mice were given subcutaneous injection with vehicle (sesame oil) or P4 (1mg/mouse) (n=3 per genotype per treatment). The uteri were collected at 6 hours after the steroid hormone injection.

2.. RNA isolation and quantitative real-time PCR {#ss4}
------------------------------------------------

Total RNA was isolated from uteri using Qiagen RNeasy total RNA isolation kit (Qiagen, Valencia, CA, USA). The expression levels of *Prap1* were quantified by RT-qPCR using an Applied Biosystems StepOnePlus system according to the manufacturer's instructions (Applied Biosystem, Foster City, CA, USA). The cDNAs were synthesized with MMLV Reverse Transcriptase (Invitrogen, Carlsbad, CA, USA) by the use of 1 μg of total RNA primed with random hexamer primers according to the manufacturer's instructions. RT-qPCR was performed on cDNA to assess the expression levels of genes of interest with primers, by using SYBR green and 96-well optical plates, with an Applied Biosystems StepOnePlus (Applied Biosystem, Foster City, CA, USA). Experimental *Prap1* data were normalized to 18S ribosomal RNA. Analysis of *Prap1* mRNA expression was first undertaken by the standard curve method, and results were corroborated by CT values assessing levels of gene expression. All data are presented as mean ± SEM. Statistical analyses were performed using Student's *t*-tests using the Instat package from GraphPad (San Diego, CA, USA). *p*\<0.05 was considered statistically significant.

3.. Immunohistochemistry {#ss5}
------------------------

Uterine sections of 5μm thickness were blocked with 10% normal goat serum in PBS (pH 7.5) for immunohistochemistry. Sections were exposed to primary anti-PRAP1 (HPA038713, Sigma-Aldrich, St. Louis, MO, USA) antibody in 10% normal goat serum in PBS (pH 7.5) overnight at 4°C. The Sections were incubated with biotinylated goat anti-rabbit 2nd antibody (BA-1000; Vector Laboratories, Burlingame, CA, USA). Following exposure to the horseradish peroxidase-conjugated streptavidin substrate, positive immunoreactivity (brown precipitate) was detected using the Vectastain Elite DAB kit (Vector Laboratories, Burlingame, CA, USA) and hematoxylin (Biocare Medical, Pacheco, CA, USA) were used for a nuclear counterstain.

RESULTS {#ss6}
=======

1.. PRAP1 is a target of ARID1A in the murine uterus {#ss7}
----------------------------------------------------

ARID1A has a critical role in modulating epithelial proliferation at the pre-implantation stage which is a critical requisite for uterine receptivity ([@ref19]). To determine transcriptional regulation of *Prap1* by ARID1A, RT-qPCR was performed in the uteri of control (*Arid1a^f/f^*) and *Pgr^cre/+^Arid1a^f/f^* (*Arid1a^d/d^*) mice ([@ref19]) at GD 3.5. The results revealed that there was a significant increase in *Prap1* mRNA expression in the *Arid1a^d/d^* mice uterus compared to the control mice ([Fig. 1A](#f1){ref-type="fig"}). This result was extended through immunohistochemistry to examine spatial expression of PRAP1 protein in the *Arid1a^d/d^* mice ([Fig. 1B](#f1){ref-type="fig"}). Control samples at GD 3.5 showed very weak PRAP1 expression within the uterine epithelial, glandular, and stromal cells. However, *Arid1a^d/d^* mice showed a remarkable increase in PRAP1 expression throughout when compared to control mice. These data suggest that the expression of PRAP1 is suppressed by ARID1A.

![The expression of PRAP1 in the uteri of control, *Arid1a^d/d^*, and PRKO mice. (A) The expression pattern of *Prap1* from control and *Arid1a^d/d^* mice uteri determined by RT-qPCR. Total RNA used for RT-qPCR assay was prepared from control and *Arid1a^d/d^* mice uteri at GD 3.5. The results represent the mean ± SEM of three independent RNA sets. *p*\>0.05. (B) The localization pattern of PRAP1 proteins by immunohistochemistry in the uteri of control (a) and *Arid1a^d/d^* (b) mice. Uterine sections were collected from control and *Arid1a^d/d^* mice at GD 3.5. PRAP1, proline-rich acidic protein 1; GD, day of gestation.](dr-23-3-277-g1){#f1}

2.. The expression of PRAP1 in the uterus during early pregnancy {#ss8}
----------------------------------------------------------------

The expression of ARID1A mRNA and protein was strongly detected on GD 0.5, which consistently expressed until GD 6.5 in the uterus ([@ref19]). To investigate the expression pattern of PRAP1 in mouse uteri during early pregnancy, we performed immunohistochemistry from GD 0.5 to GD 7.5 in the uteri of natural pregnancy ([Fig. 2](#f2){ref-type="fig"}). The initiation of pregnancy was marked by the presence of the postcoital vaginal plug (GD 0.5). At GD 0.5, PRAP1 expression was present within uterine luminal and glandular epithelium, however expression was not seen within stroma. At GD 2.5, expression increased, and was also present within stroma. At GD 3.5 and 4.5, PRAP1 levels showed a slight decrease in uterine epithelial and stromal cells. Interestingly, the expression of PRAP1 was remarkably decreased after embryo implantation GD 5.5 and 7.5. The expression of PRAP1 was not observed in the uterus including the primary and secondary decidual zone at GD 5.5 and 7.5. These data indicate that PRAP1 is tightly regulated in the uterus during early pregnancy.

![The localization pattern of PRAP1 during early pregnancy. Representative photomicrographs show immunohistochemical staining of PRAP1 proteins in the uterus from GD 0.5 to GD 7.5. The arrow indicates the embryo. PRAP1, proline-rich acidic protein 1; GD, day of gestation.](dr-23-3-277-g2){#f2}

3.. The regulation of PRAP1 by P4 in the uterus {#ss9}
-----------------------------------------------

In order to evaluate PRAP1 expression in response to P4 treatment, immunohistochemistry was performed on ovariectomized control (wild type and *Arid1a^f/f^*), *Arid1a^d/d^*, and PRKO mice treated with either vehicle or P4 for 6 hours ([Fig. 3](#f3){ref-type="fig"}). PRAP1 expression was strongly detected at luminal and glandular epithelium of the ovariectomized control mice treated with vehicle. After P4 treatment, the strong PRAP1 expression disappeared at the luminal and glandular epithelium of control mice. Both *Arid1a^d/d^* and the PRKO mice showed expression of PRAP1 after vehicle treatment. However, PRAP1 expression was not changed in *Arid1a^d/d^* and PRKO mice after P4 treatment. This data further reveals that PRAP1 is regulated by PGR and ARID1A.

![The regulation of PRAP1 expression by ARID1A and PGR in the uterus. Representative photomicrographs show the localization pattern of PRAP1 by immunohistochemistry in the vehicle or P4-treated uteri from control (a and d), *Arid1a^d/d^* (b and e), and PRKO (c and f). Uterine sections were collected from ovariectomized control, *Arid1a^d/d^*, and PRKO that were treated with vehicle (sesame oil; a-c) or P4 (d-f) for 6 hours. PRAP1, proline-rich acidic protein 1; PRKO, progesterone receptor knock-out.](dr-23-3-277-g3){#f3}

DISCUSSION {#ss10}
==========

Our study examined the regulation of *Prap1* by ARID1A and determined the expression patterns of PRAP1 in the uterus during early pregnancy and in response to ovarian steroid hormone treatment. In the present study, we report that PRAP1 expression levels are remarkably increased in mice with conditional ablation of *Arid1a* (*Arid1a^d/d^*) ([Fig. 1](#f1){ref-type="fig"}). ARID1A plays a role as a transcriptional repressor in breast cancer ([@ref12]). Loss of ARID1A profoundly alters histone modifications and the transcriptome. In response to a lack of *Arid1a*, mice did not suppress the expression of PRAP1 by P4, further confirming ARID1A is a transcriptional suppressor of *Prap1* gene.

Throughout implantation and early pregnancy, fluctuations in steroid hormone expression are exhibited. GD 0.5 and 1.5 in murine pregnancy are the days in which pre-ovulatory ovarian E2 is secreted, and proliferation occurs. From GD 2.5 on, proliferation shifts from the luminal and glandular epithelial cells to the stromal cells. Overall, we observed fluctuation of PRAP1 expression ([Fig. 2](#f2){ref-type="fig"}). At GD 2.5 expression levels were the highest overall. E2 stimulated proliferation occurs during the first two days of pregnancy in the mouse uterus ([@ref5]). Our result is consistent that PRAP1 is regulated by E2 ([@ref35]). At GD 4.5, implantation occurs, as stromal cells transition into decidual cells in response to a blastocyst (Huet-[@ref15]). We and others showed reduction of PRAP1 expression after implantation and down-regulation by P4 ([@ref6]; [@ref35]). The invading blastocyst then induces a decidualization reaction of the P4-primed stromal cells, where they differentiate into morphologically and functionally unique cells to surround the implanting embryo and support growth until placentation, all under critical continued P4 regulation ([@ref24]). Therefore, PRAP1 is a suppressed protein at the post-implantation stage.

PRKO is an invaluable model in assessing P4's role in gene and protein expression. Past research has revealed that the ablation of PGR results in abnormalities in the reproductive biology of the mouse and also a defect in the implantation process ([@ref32]). Within this study, we utilized the PRKO mouse model in order to analyze the expression of PRAP1 in response to the ablation of both PGR isoforms ([Fig. 3](#f3){ref-type="fig"}). Results showed a difference in only epithelial expression of PRAP1 in the PRKO mouse model in comparison to controls. Epithelial cells are associated with the production of paracrine factors, mediated through the PGR receptors, which are critical in enhancing epithelial differentiation and growth within the uterus ([@ref21]; [@ref8]). These results suggest that epithelial PRAP1 expression is regulated by PGR.

P4 is a steroid hormone that is critical in reproductive processes, and has been utilized for therapeutic treatment in peri-menopausal women who experience aberrant bleeding or menstrual problems ([@ref26]; [@ref4]). In order to analyze P4's effect on PRAP1 expression, we examined PRAP1 expression within control, *Arid1a^d/d^*, and PRKO mice, with both vehicle and 6-hour P4 treatment ([Fig. 3](#f3){ref-type="fig"}). In this analysis we found that P4 treatment decreased expression in the control mice. This result allows us to hypothesize P4's role in PRAP1 expression, and also allows for a connection of P4 treatment in the two different mouse models. P4 does not suppressed PRAP1 expression in the *Arid1a^d/d^* mice. PRAP1 plays normal epithelial cell homeostasis as a negative regulator and the down-regulation of *Prap1* in cancer cells may lead to dysregulated cell growth ([@ref37]). Although the regulation of PRAP1 expression by ovarian steroid hormone suggests a possible connection to uterine function, molecular mechanisms of PRAP1 regulation should be dissected in uterine function during early pregnancy.

Our results demonstrate that PRAP1 is a novel target of ARID1A and PGR in the murine uterus. Additional research within this context would provide for greater insight into the role of PRAP1 within the context of reproductive biology, and provide for a new possible therapeutic target for uterine disorders.
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